FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileInvion Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
IVX.AX
Invion Limited Stock AnalysisComprehensive stock analysis for Invion Limited (IVX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIVX.AX
IVX.AX
Invion Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
IVX.AX
  1. Home
  2. Stocks
  3. Invion Limited

Invion Limited

🇦🇺IVX.AX•ASX

Invion Limited

🇦🇺IVX.AX•ASX

Your view on IVX.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Invion Limited

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Thian Chew
Headquarters
385 Bourke Street, Melbourne, VIC, AU
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Thian Chew
Headquarters
385 Bourke Street, Melbourne, VIC, AU
Description

Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types.

Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma.

The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments.

Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Invion Limited. Starting points for Invion Limited: EPS -AUD 0.06, beta 0.40 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Invion Limited. Invion Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Invion Limited. Trailing twelve-month EPS for Invion Limited stands at -AUD 0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Invion Limited. Invion Limited has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IVX.AX19 companies
Compare IVX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACR.AXAcrux LimitedHealthcareBiotechnology—
ADR.AXAdherium LimitedHealthcareMedical - Devices—
BGT.AXBio-Gene Technology LimitedBasic MaterialsAgricultural Inputs—
BIT.AXBiotron LimitedHealthcareBiotechnology—
CAN.AXCann Group LimitedHealthcareDrug Manufacturers - Specialty & Generic—
HIQ.AXHITIQ LimitedHealthcareMedical - Healthcare Information Services—
ICR.AXIntelicare Holdings LimitedHealthcareMedical - Healthcare Information Services—
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
UPCUniverse Pharmaceuticals Inc.HealthcareNASDAQ$961,098
USMJNorth American Cannabis Holdings, Inc.HealthcareOTC$137,858
VDRMViaDerma, Inc.HealthcareOTC$493,484
VENI.CNVencanna Ventures Inc.HealthcareCNQ$1.1M
VEXT.CNVext Science, Inc.HealthcareCNQ$59.5M
VEXTFVext Science, Inc.HealthcareOTC$43.8M
VIBE.CNVibe Growth CorporationHealthcareCNQ$647,819
VIBEFVibe Growth CorporationHealthcareOTC$431,880
VIT.AXVitura Health LimitedHealthcareASX—
VIVXFAvivagen Inc.HealthcareOTC$7,769
VLS.AXVita Life Sciences LimitedHealthcareASX—
VM.VVoyageur Pharmaceuticals Ltd.HealthcareTSXV$23.1M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Invion Limited.

IVX.AX AnalysisWeak
Past
1
Growth
1
Health
4
Profit
1
Value
1